ClinicalTrials.gg
CompletedNCT07119073Fed-FastUpdated Aug 12, 2025

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)

A Phase 1 interventional study of Dexmethylphenidate in Healthy Volunteers in Fed and Fasted State, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Cingulate Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Oct 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Fasting with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Fasting · United States.

Enrollment
61st of 85
25 · median 39
Started
2024
with 2 others
Phase 1
19 of 95
1 open now
Registered
87th of 95
by date
Lead sponsor
2 of 95
Cingulate Therapeutics

Among the 95 studies in Fasting with a site in United States, this one is the 61st largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 in phase 1, and was the 87th registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

19 of the 95 studies in Fasting with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Fasting with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 50 mg trimodal tablets in healthy adult volunteers.

Read the detailed description

Fasted Arm: Following an overnight fast of at least 10.5 hours prior to dosing, subjectsshould be administered CTx-1301 (50 mg) with approximately240 mL (8 fluidounces) of water. No food should be allowed for at least 4 hours post-dose.Water can be allowed as desired except for at least one hour before and at least one hour after drug administration. Subjects should receive standardized meals as defined in the study schedule for the fasted treatment arm.

Fed Arm: Following an overnight fast of at least 10.5 hours prior to dosing, subjects should begin consuming the test meal 30 minutes prior to administration ofCTx-1301. CTx-1301 (50 mg) should be administered 30 minutes after thestart of the meal. CTx-1301 (50 mg) should be administered with approximately240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for at leastone hour before and at least one hour after drug administration. Subjects will receive the high-fat meal as described below for the fed treatment arm and standardized meals for all other meals.

A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (800 to 1000 calories) meal is used as the test meal for food-effect bioavailability (BA) and fed bioequivalence (BE) studies. This test meal allows 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. The test meal must be entirely consumed within 30 minutes prior to administration of CTx-1301; the test meal consists of two eggs fried in butter, two strips of bacon, two slices of toast with butter, four ounces of hash brown potatoes and eight ounces of whole milk.

03

Conditions studied

  • Healthy Volunteers in Fed and Fasted State

Browse trials for

Keywords

  • Healthy Normal Volunteers
  • Fed Study
  • Pharmacokinetics
  • Dexmethylphenidate
  • Bioavailability
  • d-MPH
  • dMPH
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender

    a. Male or Female

  2. Age

    1. Aged between 18 and 50 years inclusive. Weight and

    <!-- -->

    1. Body weight ≥ 50 kg
    2. BMI ≥ 18 and ≤ 30

4. Compliance

  1. Understands and is willing, able, and likely to comply with all study procedures and restrictions.
  2. Able to fully consume the required fed meal within 30 minutes without substitutions.
  3. If sexually active, male subjects must use an acceptable method of , which includes the double-barrier method (condom and spermicide) or agree to remain abstinent from heterosexual intercourse from Qualification day, during the study, and for 90 days following the last administration of study drug.
  4. If sexually active, female subjects of must use an acceptable method of contraception, which includes, hormonal contraceptives, intrauterine device (IUD) with or without hormones, or double-barrier method (e.g. condom and spermicide), or remain abstinent from heterosexual intercourse for 30 days prior to screening during the study and for 30 days following the last administration of study drug.
  5. Male subjects must agree not to donate sperm during the study and for 90 days following the last administration of study drug.
  6. Female subjects must agree not to donate eggs during the study and for 30 days following the last administration of study drug.

    5. Consent

a. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written (signed and dated) obtained before any study-related activities are performed.

6. General Health

  1. Good general health (in the opinion of an investigator) with no or relevant abnormalities on medical history, laboratory results, or physical examination which could affect the safety of the subject or integrity of study data.
  2. No signs of illness (fever or vomiting) within 24-hours of admission on Qualification day and check-in at Day -1
  3. Subject has sufficient venous access at the time of screening to allow cannulation and/or venipuncture to obtain the required volume of blood for this study.

    7. Smoking/Caffeine/Alcohol

<!-- -->

  1. Subject must be a non-smoker (i.e., does not use any form of nicotine products) as defined by exclusion #4 in this protocol.
  2. Subject must be able to refrain from caffeine or xanthine-containing beverages or foods (e.g., tea, coffee, chocolate, cola) for 24 hours prior to admission on Qualification day, check-in at Day -1 and for the duration of the stay at the study center until EOS.
  3. Subject must be able to refrain from using alcohol 48 hrs. prior to admission on Qualification day, check-in at Day -1 and for the duration of the stay at the study center until EOS.

    8. Medications

a. Subject must be willing and able to take stimulant medications during participation in this trial.

9. Qualification

a. Subject satisfactorily completes the Qualification day, is able to safely tolerate 30 mg Focalin™ XR, and general behavior suggests that the subject could successfully complete the study in the opinion of an investigator.

Exclusion criteria

Exclusion Criteria:

  1. Medical History

    1. Current and/or recurrent disease or illness that, in the opinion of an investigator, could affect the study conduct, study outcome, subject safety, or pharmacokinetic (PK) assessments (e.g., hepatic disorders, renal insufficiency, non-self-limiting gastrointestinal disorders, weight loss surgeries).
    2. Any history including but not limited to arterial hypertension, pulmonary arterial hypertension, myocardial infarction, peripheral vascular disease, stroke, or evidence of other cardiovascular disease or disorder, including but not limited to abnormalities such as:

      • measurement corrected for heart rate according to the Fridericia rule (QTcF) >450 msec for males or >470 msec for female subjects during controlled rest at screening, qualification, and Day -1,
      • Family history of long QT syndrome,
      • Family history of congenital QT prolongation,
      • PR (PQ) interval shortening \<120 msec (PR \<120 msec but >110 msec is acceptable if there is no evidence of ventricular pre-excitation),
      • PR (PQ) interval prolongation (>220 msec), intermittent second-degree (Wenckebach block while asleep or in deep rest is not exclusionary), or third-degree atrioventricular block,
      • Persistent or intermittent complete bundle branch block (BBB) or intraventricular conduction delay (IVCD) with QRS >110 msec.
    3. Current and/or previous history of any other serious, severe or unstable psychiatric illness which in the opinion of the investigator, may require treatment (e.g. anxiety, psychosis, mood disorder, motor tics or suicidality) or make the subject unlikely to fully complete the study, and/or any condition that presents undue risk from the study medication or procedures.
    4. Subject has had suicidal thoughts within the last 6 months as supported by the Columbia Suicide Severity Rating Scale (C-SSRS).
    5. Positive test results for (HIV)-1/HIV-2 antibodies, surface antigen (HBsAg) or virus antibody (HCVAb).
    6. A family history of sudden cardiac or unexplained death.
    7. Any condition or abnormal laboratory finding that could result in harm to the subject, affect the outcome of the study or suggest unstable medical illness.
    8. Any clinically significant psychiatric disorder or finding which the Investigator considers the subject disqualified from the study.
    9. Subject plans to undergo elective procedures/surgery at any time during the study.
    10. Subject has had surgery within the past 90 days.
    11. Subject of is pregnant or planning to become pregnant during the duration of the study or within 30 days of the end of the study.
    12. Subject is breast-feeding during the study or within 30 days following the study.
  2. Medications a. Subject has taken any medication that, in the opinion of an Investigator, has been shown to alter the PK of d-MPH.

    b. Use of any prescription medication within 14 days prior to Qualification and Day -1 and/or use of any OTC medications (such as antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) within 7 days prior to Qualification and Day -1, unless jointly approved by an Investigator and Sponsor. Subjects may not use these medications for the full duration of the stay at the study center until EOS.

    i. Subjects are permitted to take hormonal and hormone replacement therapy at acceptable levels if stable at least 30 days prior to Qualification, through the duration of the study, and for 30 days after the study ends.

    ii. Acetaminophen (up to 2 grams per day) may be used during the study under the direction of the Investigator.

    iii. COVID vaccine is allowed if taken at least 45 days prior to Qualification Protocol CTx-1301-013 Version 1.0 Page 25 of 49 CONFIDENTIAL iv. On a case-by-case basis, an Investigator is permitted to allow the use of certain concomitant medications, for example, to treat an AE, as long as an Investigator determines that the medication will not affect the subject's safety or study integrity (e.g., topical medications).

  3. Alcohol/Substance Abuse

    a. Lifetime history of alcohol or other substance abuse. b. Subject has positive urine alcohol test or urine screen for drugs of abuse at screening, qualification or check-in. (Screening visit urine MPH screen results are not required prior to Qualification day but are necessary prior to randomization on Day -1. Day-1 urine MPH screen results are not required prior to dosing in each Period).

  4. Smoking

    a. Subject is a current smoker or has recently discontinued smoking (i.e., regular use of any nicotinecontaining products within 3 months of screening). Occasional, social use, or routine environmental exposure to nicotine is acceptable.

  5. Allergy/Intolerance

    a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or any other allergy, which, in the opinion of an Investigator, contraindicates their participation.

  6. Clinical Studies

    a. Receipt of an drug within the 30 days before screening day. b. Previous participation in a CTx-1301 study.

  7. Personnel

    a. An employee of the sponsor, study site, or members of their immediate family.

  8. Blood

    1. Subject has donated blood within 56 days prior to screening, plasma within 7 days prior to screening, or experienced significant blood loss (excess of 500 mL) within 3 months prior to screening and for the duration of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    CTx-1301 Fasted

    Subjects will receive CTx-1301 in a fasted state

    Drug: Dexmethylphenidate

  • Active comparator
    CTx-1301 Fed

    Subjects will receive CTx-1301 in a fed state (high fat test meal)

    Drug: Dexmethylphenidate

Interventions

  • Subjects will be randomized to one of two sequences. Subjects will be dosed with 50 mg dose of Cox-1301 during each sequence. Subjects will serve as their own control.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter (Cmax)

    Maximum Concentration

    Time frame: Hour 0 to hour 28

  2. Pharmacokinetic parameter (AUC0-inf)

    Area Under the Curve from time 0 to infinity

    Time frame: Hour 0 to hour 28

  3. Pharmacokinetic parameter (AUC0-last)

    Area Under the Curve from time 0 to 28 hrs

    Time frame: Hour 0 to hour 28

Secondary outcomes

  1. Pharmacokinetic parameter K

    Terminal Elimination Constant

    Time frame: Hour 0 to hour 28

  2. Pharmacokinetic parameter T 1/2

    Half Life

    Time frame: Hour 0 to hour 28

  3. Pharmacokinetic parameter T max

    Time of Maximum Concentration

    Time frame: Hour 0 to hour 28

  4. Pharmacokinetic parameter T lag

    Lag time

    Time frame: Hour 0 to hour 28

  5. Pharmacokinetic parameter Cl/F

    Apparent Clearance

    Time frame: Hour 0 to hour 28

  6. Pharmacokinetic parameter Vd/F

    Apparent Volume of Distribution

    Time frame: Hour 0 to hour 28

  7. Partial AUC

    Area Under the Curve

    Time frame: 0-3 hrs

  8. Partial AUC

    Area Under the Curve

    Time frame: 3-6 hrs

  9. Partial AUC

    Area Under the Curve

    Time frame: 3-7 hrs

  10. Partial AUC

    Area Under the Curve

    Time frame: 6-9 hrs

  11. Partial AUC

    Area Under the Curve

    Time frame: 7-12 hrs

  12. Partial AUC

    Area Under the Curve

    Time frame: 9-12 hrs

  13. Partial AUC

    Area Under the Curve

    Time frame: 12-16 hrs

  14. Safety - ECG

    Evaluation of changes in ECG measurements; heart rate, PR interval, RR interval, QT interval, QTc with Bazett correction, QTc with Fredericia correction intervals, and QRS duration.

    Time frame: Day -1 to Day 4

  15. Safety - Vital Signs

    Evaluation of changes in Vital Sign measurements to include blood pressure (mmhg).

    Time frame: Day -1 to Day 4

  16. Safety - Vital Signs

    Evaluation of changes in Vital Sign measurements to include weight (kg).

    Time frame: Day -1 to Day 4

  17. Safety - Vital Signs

    Evaluation of changes in Vital Sign measurements to include heart rate (bpm).

    Time frame: Day -1 to Day 4

  18. Safety - Vital Signs

    Evaluation of changes in Vital Sign measurements to include height (cm).

    Time frame: Day -1 to Day 4

  19. Safety - Vital Signs

    Evaluation of Vital Sign measurements to include weight and height combined to report BMI in kg/m\^2.

    Time frame: Day -1 to Day 4

  20. Safety - Safety Labs

    Evaluation of changes in Safety Lab measurements to include hematology, biochemistry, thyroid, serology, urinalysis, and drugs of abuse.

    Time frame: Day -1 to Day 4

  21. Safety - Physical Exam

    Evaluation of changes in the Physical Exam to include general appearance, skin, head, eyes, ears, nose, throat, neck, spine, psychiatric, respiratory, cardiovascular, gastrointestinal, musculoskeletal, central nervous system, lymphatic, endocrine.

    Time frame: Day -1 to Day 4

  22. Safety - C-SSRS

    C-SSRS is a tool designed to access and track suicidal adverse events (suicidal behavior and suicidal ideation).

    Time frame: Day -1 to Day 4

  23. Safety - Treatment Emergent Adverse Events (TEAEs)

    Evaluation of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Day -1 to Day 4

07

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2024, 1 month.

Of 18 phase 1 interventional studies under Fasting, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 3. This study's 1 month is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
Aug 12, 2025
StartActual
Oct 31, 2024
Primary completionActual
Dec 21, 2024
CompletionActual
Dec 27, 2024
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119073
Lead sponsor
Cingulate Therapeutics
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Oct 31, 2024
Primary completion
Dec 21, 2024
Completion
Dec 27, 2024
Last update
Aug 12, 2025

Study contacts

Matt Brams, MD
study director · Cingulate Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion